What is Pheast?
Founded in 2020 and headquartered in Palo Alto, California, Pheast Therapeutics is a cancer immunotherapy company. The company is dedicated to developing novel checkpoint therapies designed to leverage the innate immune system for combating cancer. This strategic focus positions Pheast at the forefront of innovative oncology treatments, aiming to unlock new therapeutic avenues for patients.
How much funding has Pheast raised?
Pheast has raised a total of $76M across 1 funding round:
Series A
$76M
Series A (2022): $76M with participation from ARCH VENTURE PARTNERS, Catalio Capital Management, Alexandria Venture Investments, and Risk and Return
Key Investors in Pheast
ARCH VENTURE PARTNERS
ARCH Venture Partners is a leading early-stage venture capital firm that creates and invests in life sciences and advanced technology companies, often co-founding startups with scientists and entrepreneurs to commercialize innovations from universities, corporate R&D groups, and national laboratories.
Catalio Capital Management
Catalio Capital Management is a New York-based investment firm specializing in innovative healthcare investing across private, public, and credit markets, focusing on breakthrough biomedical technology companies.
Risk and Return
RSquared VC is a venture capital firm focused on investing in companies that enhance national resilience and address various risks, supporting innovative solutions that contribute to the stability and security of communities.
What's next for Pheast?
The recent major strategic investment signals a pivotal growth phase for Pheast Therapeutics. This capital infusion is expected to accelerate the company's research and development pipeline, potentially enabling the advancement of its novel checkpoint therapies through critical clinical milestones. The company's focus on harnessing the innate immune system suggests a forward-looking approach to cancer treatment, aiming for more effective and less toxic therapeutic options.
See full Pheast company page
